C. Ottensmeier, et al. ASCO 2023 Abstract available on the ASCO website – Download the abstract and the posterPoster Presentation
Category: TG4050
Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Transgene to present data on its two therapeutic cancer vaccines at the 2023 ASCO annual meeting
Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer
A. Lalane et al.AACR 2023Download the poster herePoster Presentation
New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
New Data Showing that Transgene and NEC’s TG4050 induces strong and specific immune responses against tumors presented at AACR 15
Availability of Transgene’s 2022 Universal Registration Document
Availability of Transgene’s 2022 Universal Registration Document 15
Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers
Transgene to host KOL webinar on TG4050 15
Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
Transgene to present multiple posters highlighting the potential of its exciting immunotherapy pipeline at AACR2023 15
R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
TRANSGENE R&D DAY
Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)
JP Delord, et al. ASCO 2022 Abstract available on the ASCO website – Download the poster here Poster Presentation
Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
Transgene presented additional Phase I Data with TG4050 at ASCO 2022
